Website: https://vjfc.nifc.gov.vn/
Website: https://vjfc.nifc.gov.vn/
N-nitrosamines in food products are a serious health threat due to their carcinogenic and non-carcinogenic effects on the kidneys, spleen, GIT, and liver. Meat products are a major source of their exposure. Within a joint Russian-Vietnamese study, health risks for the Vietnam population were assessed using the methodology developed in the Eurasian Economic Union. As a result, unacceptable risk levels associated with Nnitrosodimethylamine (NDMA) in meat products were established for children under 6 years and adults 18-50 years old. However, the reference dose for NDMA established by the US EPA is based on limited data and requires experimental definition. The objective of this study is to overview the publications devoted to the study of the toxic effects of N-nitrosamines and to justify an experiment design for identifying and validating biomarkers of exposure and response upon N-nitrosamines’ exposure. In conformity with the international standards OECD and GLP principles, a design is going to be created for a 180-day experimental study of NDMA chronic toxicity using Wistar rats. The number of animal groups exposed to NDMA is four, and one group is control. Oral exposure to NDMA will take place using gavage 7 days a week. The experiment involves monthly monitoring of biochemical indicators (AST, ALT, and GGT) and NDMA levels in blood. The created design is expected to help establish points of departure (reference level, benchmark dose level) for chronic exposure as well as provide significant data for risk assessment. Taking into account three established approaches used in experimental studies to refine risk assessment’s parameters, the Benchmark dose (BMD) method was selected for this experiment’s design.
N-nitrosamines, toxicological experiment, health risk assessment, hepatotoxicity, biomarkers.
[1]. D. V. Suvorov, N. V. Zaitseva, P. Z. Shur et.al., “Health risk assessment associated with priority potentially hazardous chemical compounds detected in canned meat and meat-and-vegetable food for infants,” Problems of Nutrition, vol. 92, no. 4, pp. 38-48, 2023.
[2]. M. Hidajat, D. M. McElvenny, P. Ritchie, et al., “Lifetime exposure to rubber dusts, fumes and N-nitrosamines and cancer mortality in a cohort of British rubber workers with 49 years follow-up,” Occupational & Environmental Medicine (OEM), vol. 76, no. 4, pp. 250-258, 2019.
[3]. M. Boniol, A. Koechlin, P. Boyle, “Meta-analysis of occupational exposures in the rubber manufacturing industry and risk of cancer,” International Journal of Epidemiology, vol. 46, no. 6, pp. 1940-1947, 2017.
[4]. A. Roszczenko, J. Jablonski, Moniuszko-Jakoniuk J., “Effect of N-nitrosodimethylamine (NDMA) on activity of selected enzymes in blood serum of the rat,” Medycyna Pracy, no. 47, pp. 49-53, 1996.
[5]. K. F. Chooi, D. B. Rajendran, S. S. Phang, H. H. Toh, “The dimethylnitrosamine induced liver fibrosis model in the rat,” Journal of Visualized Experiments, no. 112, e54208, 2016.
[6]. M. Lathouri, A. Korre, M. Dusinska, S. Durucan, Human Health hazard assessment strategy for amine emissions around PCC facilities. Deliverable D3.3. Sustainable OPEration of post-combustion Capture plants (SCOPE), 2022.
[7]. S. Özbay, U. Şireli, “The effect of ascorbic acid, storage period and packaging material on the formation of volatile N-nitrosamine in sausages,” Journal of Food Science and Technology, no.59, 2021.
[8]. H. Lee, “Dietary exposure assessment for volatile N-nitrosamines from food and beverages for the U.S. population,” Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment, no. 41, pp. 1-12, 2024.
[9]. Technical Regulations of the Customs Union 021/2011 “On the safety of food products” [Online]. Available: https://eec.eaeunion.org/upload/medialibrary/6ad/TR-TS-PishevayaProd.pdf [Accessed 07/04/2025] (in Russian).
[10]. Health risks assessment associated with n-nitrosamines content in meat and meat products consumed by the population of the Socialist Republic of Vietnam. Report on Research work № 123121900014-8. Registered in the Russian Federation’s Scientific base. 2022.
[11]. Toxicological Profile for N-Nitrosodimethylamine (NDMA). USA, Atlanta: Agency for Toxic Substances and Disease Registry, 2023.
[12]. L. M. Anderson, A. Giner-Sorolla, D. Ebeling, J.M. Budinger, “Effects of imipramine, nitrite, and dimethylnitrosamine on reproduction in mice,” Research Communications in Chemical Pathology and Pharmacology, no. 19, pp. 311-327, 1978.
[13]. Provisional Peer Reviewed Toxicity Values for N-Nitrosodimethylamine (CASRN 62-75-9). USA, Cincinnati: U.S. Environmental Protection Agency, 2007.
[14]. S. A. Sheweita, M. H. Mostafa, “N-Nitrosamines and their effects on the level of glutathione, glutathione reductase and glutathione S-transferase activities in the liver of male mice,” Cancer Letters, vol. 99, no. 1, pp. 29-34, 1996.
[15]. D. V. Suvorov, P. Z. Shur, S. E. Zelenkin, “On the issue of determining tolerable daily intake of total N-nitrosamines for toddlers,” Health Risk Analysis, no. 4, pp. 72-80, 2024.
[16]. J. Gao, G. J. Wang, Z. Wang et.al., “High CYP2E1 activity correlates with hepatofibrogenesis induced by nitrosamines,” Oncotarget, vol. 8, no 68, pp. 112199–112210, 2017.
[17]. S. D. Khanna, D. Puri, “The hepatotoxic effects of dimethyl- nitrosamine in the rat,” Journal of Pathology and Bacteriology, no. 91, pp. 605-608, 1966.
[18]. J. Moniuszko-Jakoniuk, A. Roszczenko, J. Dzieciol, “Influence of low concentrations of N-nitrosodimethylamine on the iron level and histopathological picture of rats liver, spleen and bone marrow,” Acta Poloniae Toxicologica, vol. 7, no. 2, pp. 179-186, 1999.
[19]. M. Lathouri, A. Korre, M. Dusinska, S. Durucan, Human Health hazard assessment strategy for amine emissions around PCC facilities. Deliverable D3.3. Trondheim, Norway: Sustainable OPEration of post-combustion Capture plants (SCOPE), 2022.
[20]. X. Yang, W.F. Salminen, L.K. Schnackenberg, “Current and emerging biomarkers of hepatotoxicity,” Current Biomarker Findings, no. 2, pp. 43-55, 2012.
[21]. M. Shashikala, R. Rohini, M. Ceema, R.M. Ganga, M. Shaheda, “Comprehensive Review on Biomarkers in Hepatotoxicity: From Conventional Indicators to Omics‑Driven Discoveries,” Biosciences Biotechnology Research Asia, vol. 22, no. 3, 2025.
[22]. H. Guo, X. Xu, J. Zhang et.al., “The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies,” Pharmaceuticals, vol. 17, 2024.
[23]. V. Chaurasia, M. L. Aggarwal, M. C. Garg, “Biochemical and Histological Evaluation of Penoxsulam Herbicide on an Animal Model,” Journal of Pharmaceutical Research International, vol. 34, no. 4B, pp. 12-23, 2022.
[24]. OECD, Test No. 452: Chronic Toxicity Studies. Paris: OECD Publishing, 2018.
[25]. K. Kogure, M. Ishizaki, Nemoto M. et.al., “A comparative study of the anatomy of rat and human livers,” Journal of Hepato-Biliary-Pancreatic Sciences, no. 6, pp. 171-175, 1999.
[26]. A. Muzhikyan, K. Zaikin, J. Guschin et.al., “Comparative morphology of human and laboratory animal’s liver and gall bladder,” International Journal of Veterinary Medicine, no. 4, pp. 117-127, 2017.
[27]. M. Stojanović, M. B. Čolović, J. Lalatović et.al., “Monolacunary Wells-Dawson Polyoxometalate as a Novel Contrast Agent for Computed Tomography: A Comprehensive Study on In Vivo Toxicity and Biodistribution,” International Journal of Molecular Sciences, no. 25, pp. 2569, 2024.
[28]. R. Wilson, “Predicting the carcinogenicity of chemicals in humans from rodent bioassay data,” Environmental Health Perspectives, no. 94, pp. 195-218, 1991.
[29]. D.O. Shatalov, S.A. Kedik, N.V. Krupenchenkova et.al., “Acute Toxicity of The Pharmaceutical Substance Branched Oligohexamethyleneguanidine Hydrochloride at Mice and Rats after Intragastric Administration,” American Journal of Biomedical Science & Research, vol. 2, no. 4, pp. 76-77, 2019.
[30]. OECD Principles on Good Laboratory Practice. Paris: Environment Directorate Organisation for Economic Co-operation and Development, 1998.
[31]. M. Akinaw, S. P. Nair, R. E. Usure et.al., “Nephroprotective Effect of the Leaf Extract of Ajuga remota Benth Against Gentamicin-Induced Nephrotoxicity in Swiss Albino Mice,” Journal of Experimental Pharmacology, no. 16, pp. 159 – 171, 2024.
[32]. OECD Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453: Second edition. Paris: OECD Publishing, 2014.
[33]. A. M. Lynch, J. Howe, D. Hildebrand, J. S. Harvey, M. Burman, D. S. G. Harte, L. Chen, C. Kmett, W. Shi, C. F. McHugh, K. K. Patel, V. Junnotula, J. Kenny, R. Haworth, J. W. Wills, “N-Nitrosodimethylamine investigations in Muta™ Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations,” Mutagenesis, vol. 39, pp. 96-118, 2024.
[34]. R. Peto, R. Gray, P. Brantom, P. Grasso, “Nitrosamine carcinogenesis in 5120 rodents: chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting (3, 6 or 20 weeks) and of species (rats, mice or hamsters),” IARC Scientific Publications, vol. 57, pp. 627-665, 1984.
[35]. J. T. Alves, L. Magalhães, J. V. Francisco de Aquino, O. G. Vitale, G. F. Rosalem, G. K. Marraschi, R. L. M. Castro, S. T. C. Dos Santos, L. T. Nagaoka, J. Stein, H. Hisano, B. C. Jorge, A. C. Arena, “Combined Maternal and Paternal Low‐Dose N‐Nitrosodimethylamine Exposure: Maternal Alterations and Developmental Toxicity in Rats,” Birth Defects Research, no. 117, 2025.
[36]. F. Sewell, J. M. Edwards, H. Prior, et.al., “Opportunities to Apply the 3Rs in Safety Assessment Programs,” ILAR Journal, vol. 57, no. 2, pp. 234–245, 2022.
[37]. J. R. Buchanan, L. T. Burka, R. L. Melnick, “Purpose and guidelines for toxicokinetic studies within the National Toxicology Program.,” Environmental Health Perspectives, no. 105, pp. 468 – 471, 1997.
[38]. S. Solanki, Y. Yadav, S. Dutta et.al., “Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent.,” Cureus, vol. 14, no. 8, p. e28097, 2022.
[39]. U.S. EPA Benchmark Dose Technical Guidance. (EPA/100/R-12/001). Washington, DC: Risk Assessment Forum, 2012.
[40]. European Food Safety Authority (EFSA) Scientific Committee, “Update: use of the benchmark dose approach in risk assessment,” EFSA Journal, vol. 15, no. 1, pp. 1-41, 2017.
[41]. N. Tsamandouras, A. Rostami-Hodjegan, L. Aarons, “Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data,” British Journal of Clinical Pharmacology, vol. 79, no. 1, pp. 48-55, 2013.